Total trials
468
Active
112
Phase 3
20
Total enrollment
344,531
Pipeline matrix
Showing 39 of 39 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Alendronate 70mg weekly | — | — | — | — | — | 1 | |
| OAC will be discontinued for the duration of the trial | — | — | — | — | — | 1 | |
| JARDIANCE 25mg | — | — | — | — | — | 1 | |
| SGLT-2 inhibitor | — | — | — | — | — | 1 | |
| Bisacodyl | — | — | — | — | — | 1 | |
| Macrogol 3350 and electrolytes | — | — | — | — | — | 1 | |
| A combination of macrogol 3350 and electrolytes and bisacodyl | — | — | — | — | — | 1 | |
| PK-model to decide when to dose Vedolizumab and Ustekinumab | — | — | — | — | — | 1 | |
| Short duration of aspirin and prasugrel | — | — | — | — | — | 1 | |
| Conventional duration of aspirin and prasugrel | — | — | — | — | — | 1 | |
| The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. | — | — | — | — | — | 1 | |
| Protein pump inhibitor. | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | 2 | ||
| tacrolimus | — | — | — | — | 2 | ||
| Noradrenaline | — | — | — | — | — | 1 | |
| Methylphenidate | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 2 | |
| Saline | — | — | — | — | 3 | ||
| Verteporfin | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| Ipilimumab | — | — | — | — | — | 1 | |
| amiloride | — | — | — | — | — | 1 | |
| Faecal microbiota transplantation | — | — | — | — | — | 1 | |
| oral Semaglutide/Rybelsus | — | — | — | — | — | 1 | |
| Dasatinib 100 Mg Oral | — | — | — | — | — | 1 | |
| 68Ga-FAP-2286 | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Camostat Mesylate | — | — | — | — | — | 1 | |
| SGLT2i | — | — | — | — | — | 1 | |
| Allergen Immunotherapy Extract | — | — | — | — | — | 1 | |
| ABU bladder lavage | — | — | — | — | — | 1 | |
| Saline bladder lavage | — | — | — | — | — | 1 | |
| Atorvastatin 80mg | — | — | — | — | — | 1 | |
| Blood samples | — | — | — | — | — | 1 | |
| Carvedilol | — | — | — | — | — | 1 | |
| Metoprolol Succinate | — | — | — | — | — | 1 |
Next readouts
- 2025-08-01
- 2025-12-31
- 2026-01-15
- 2026-03-01
- 2026-03-30
- 2026-03-31
- 2026-04-01
- 2026-04-30
- 2026-08-01
- 2026-09
Top conditions
- Quality of Life12
- Type 2 Diabetes10
- Coronary Artery Disease9
- Prostate Cancer9
- Pain9
- Polycystic Ovary Syndrome9
- Diabetes Mellitus8
- Lymphedema8
Frequently asked questions about Odense University Hospital
- How many clinical trials does Odense University Hospital have on ClinicalTrials.gov?
- Odense University Hospital is listed as the lead sponsor on 468 clinical trials in ClinicalTrials.gov, 112 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Odense University Hospital's trials are in Phase 3?
- 20 of Odense University Hospital's trials are in Phase 3, spread across 39 active drug programs.
- What therapeutic areas does Odense University Hospital focus on?
- Odense University Hospital's most-studied conditions on ClinicalTrials.gov are Quality of Life, Type 2 Diabetes, Coronary Artery Disease, Prostate Cancer, Pain.
- When are Odense University Hospital's next clinical trial readouts?
- Odense University Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease”, expected around 2025-08-01.